Citius Oncology, Inc. CTOR Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s retained earnings?
- Citius Oncology, Inc. (CTOR) reported retained earnings of -$96.18M in Q1 2026.
- How has Citius Oncology, Inc.'s retained earnings changed year-over-year?
- Citius Oncology, Inc.'s retained earnings decreased by 79.2% year-over-year, from -$53.67M to -$96.18M.
- What is the long-term trend for Citius Oncology, Inc.'s retained earnings?
- Over 3 years (2022 to 2025), Citius Oncology, Inc.'s retained earnings has grown at a 1750.1% compound annual growth rate (CAGR), from -$10.11K to -$64.04M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.